Emyria

Australia offers MDMA drug therapy for PTSD, a world first

In a recent article by the Washington Post, Emyria is spotlighted exploring the potential of MDMA-based therapy. 

In partnership with the Pax Centre, Emyria is bringing a multidisciplinary approach to patient care while deploying cutting-edge technology like Palantir Foundry to analyse key Real-World data outcomes for patients. This strategic approach not only facilitates the provision of these emerging treatments but also helps generate the evidence necessary to ensure their safety, engage payers and make improvements to the care models and treatments themselves. 

Collaborating with Matthew Piggott at the University of Western Australia, Emyria is also  engaged in a novel drug discovery program inspired by MDMA, showing promising potential for treatments beyond mental health. 

As Australia pioneers the rescheduling of MDMA as a controlled substance for therapeutic use beginning July 1st, Emyria stands at the forefront, prepared to make a significant impact in the field. Follow Emyria's exciting journey here: https://investorhub.emyria.com/announcements.